Pharmacyclics

4 US pharma execs make Forbes 400 list
4 US pharma execs make Forbes 400 list
BioPharma Dive
Patrick Soon-Shiong
NantWorks
Phillip Frost
OPKO Health
Randal Kirk
Intrexon
Robert Duggan
Pharmacyclics
Flag link:
Why AbbVie Inc Spent $21 Billion to Buy Pharmacyclics
Why AbbVie Inc Spent $21 Billion to Buy Pharmacyclics
Motley Fool
AbbVie
Pharmacyclics
M&A
Flag link:
Did AbbVie Blow $21 Billion Buying Pharmacyclics?
Did AbbVie Blow $21 Billion Buying Pharmacyclics?
Motley Fool
AbbVie
Pharmacyclics
M&A
Flag link:
In pharma M&A, 2015 trumps red-hot 2014 so far, report says
In pharma M&A, 2015 trumps red-hot 2014 so far, report says
Fierce Pharma
M&A
Teva Pharmaceutical
Allergan
AbbVie
Pharmacyclics
Perrigo
Mylan Labs
Flag link:
2015’s Top 6 Big Pharma Headlines Thus Far
2015’s Top 6 Big Pharma Headlines Thus Far
Motley Fool
Pfizer
M&A
Hospira
AbbVie
Pharmacyclics
PCSK9 inhibitors
Amgen
Sanofi
Regeneron
Express Scripts
Bristol-Myers Squibb
Opdivo
Flag link:
Ex-Pharmacyclics team raises $33.5M for checkpoint drug
Ex-Pharmacyclics team raises $33.5M for checkpoint drug
Fierce Biotech
Pharmacyclics
Corvus Pharmaceuticals
Flag link:
For Pharma, the Hollywood Model of Buying Pipeline Hits is not a Panacea
For Pharma, the Hollywood Model of Buying Pipeline Hits is not a Panacea
WSJ Pharmalot
JNJ
Gilead Sciences
hepatitis C
Pharmacyclics
Flag link:
Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales
Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales
Fierce Pharma
AbbVie
Humira
biosimilars
Pharmacyclics
Flag link:
AbbVie Completes Acquisition of Pharmacyclics
AbbVie Completes Acquisition of Pharmacyclics
Yahoo
AbbVie
Pharmacyclics
M&A
Flag link:
The Most Loved Biotechs of Big Hedge Funds
The Most Loved Biotechs of Big Hedge Funds
24/7 Wall St
biotech
Pharmacyclics
Gilead Sciences
Regeneron
Celgene
Amgen
Flag link:
Abbvie specifies breakdown of $21 billion Pharmacyclics deal
Abbvie specifies breakdown of $21 billion Pharmacyclics deal
Yahoo/AP
AbbVie
Pharmacyclics
M&A
Flag link:
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
Yahoo
AbbVie
Pharmacyclics
M&A
Flag link:
Pharmacyclics-AbbVie Merger Has Many Moving Parts
Pharmacyclics-AbbVie Merger Has Many Moving Parts
Seeking Alpha
AbbVie
Pharmacyclics
M&A
Flag link:
AbbVie Again Extends Exchange Offer to Acquire Pharmacyclics, Inc.
AbbVie Again Extends Exchange Offer to Acquire Pharmacyclics, Inc.
Marketwatch
AbbVie
Pharmacyclics
M&A
Flag link:
Pharmacyclics tops 1Q profit forecasts
Pharmacyclics tops 1Q profit forecasts
Yahoo/AP
Pharmacyclics
earnings
Flag link:
Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says
Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says
Fierce Pharma
JNJ
M&A
Pharmacyclics
AbbVie
Alex Gorsky
Flag link:
Is AbbVie Inc. Stock About to Crash?
Is AbbVie Inc. Stock About to Crash?
Motley Fool
AbbVie
Pharmacyclics
Flag link:
The Pharmacyclics–AbbVie Merger: What Are the Details?
The Pharmacyclics–AbbVie Merger: What Are the Details?
Yahoo/Market Realist
Pharmacyclics
AbbVie
M&A
Flag link:
Could the Pharmacyclics–AbbVie Merger Get Competitive?
Could the Pharmacyclics–AbbVie Merger Get Competitive?
Yahoo/Market Realist
AbbVie
Pharmacyclics
M&A
JNJ
Flag link:
FDA panel recommends unblinding study after Imbruvica shows clear benefit
FDA panel recommends unblinding study after Imbruvica shows clear benefit
Yahoo/Reuters
FDA
advisory panels
Imbruvica
Pharmacyclics
JNJ
AbbVie
Flag link:

Pages